Pfizer Announces Positive Top-Line Results From Phase 3 Study Of Hemophilia B Gene Therapy Candidate

December 29, 2022 03:49 AM PST | By Reuters
Follow us on Google News:

Dec 29 (Reuters) - Pfizer Inc:

* PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF HEMOPHILIA B GENE THERAPY CANDIDATE

* PFIZER - BENEGENE-2 STUDY FOR TREATMENT OF ADULT MALES WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B MET ITS PRIMARY ENDPOINT

* PFIZER - FIDANACOGENE ELAPARVOVEC WAS GENERALLY WELL-TOLERATED, WITH A SAFETY PROFILE CONSISTENT WITH PHASE 1/2 RESULTS

* PFIZER - KEY SECONDARY ENDPOINTS DEMONSTRATED A 78% REDUCTION IN TREATED ABR AND A 92% REDUCTION IN ANNUALIZED INFUSION RATE Further company coverage:


Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.



Top Listed Companies